SG Americas Securities LLC Purchases Shares of 5,340 The Medicines Company (MDCO)

SG Americas Securities LLC purchased a new stake in The Medicines Company (NASDAQ:MDCO) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 5,340 shares of the company’s stock, valued at approximately $198,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. State of Wisconsin Investment Board bought a new stake in shares of The Medicines in the 2nd quarter valued at approximately $1,977,000. State Street Corp grew its stake in shares of The Medicines by 9.0% in the 2nd quarter. State Street Corp now owns 2,220,199 shares of the company’s stock valued at $84,391,000 after buying an additional 183,086 shares in the last quarter. Royal Bank of Canada grew its stake in shares of The Medicines by 247.7% in the 2nd quarter. Royal Bank of Canada now owns 117,744 shares of the company’s stock valued at $4,476,000 after buying an additional 83,882 shares in the last quarter. Federated Investors Inc. PA grew its stake in shares of The Medicines by 3.4% in the 2nd quarter. Federated Investors Inc. PA now owns 110,574 shares of the company’s stock valued at $4,203,000 after buying an additional 3,611 shares in the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of The Medicines by 1.6% in the 2nd quarter. Alliancebernstein L.P. now owns 1,213,668 shares of the company’s stock valued at $46,132,000 after buying an additional 19,043 shares in the last quarter.

In related news, CEO Clive Meanwell sold 136,250 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $27.24, for a total value of $3,711,450.00. Following the completion of the sale, the chief executive officer now directly owns 587,652 shares in the company, valued at approximately $16,007,640.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Alexander J. Denner bought 170,000 shares of The Medicines stock in a transaction that occurred on Wednesday, November 29th. The stock was bought at an average price of $30.03 per share, with a total value of $5,105,100.00. Following the completion of the acquisition, the director now owns 6,663 shares in the company, valued at approximately $200,089.89. The disclosure for this purchase can be found here. 8.22% of the stock is currently owned by insiders.

Several equities research analysts recently commented on MDCO shares. Chardan Capital reissued a “buy” rating and issued a $85.00 price target (up previously from $80.00) on shares of The Medicines in a research note on Tuesday, August 29th. Jefferies Group reissued a “buy” rating and issued a $54.00 price target on shares of The Medicines in a research note on Thursday, September 14th. Oppenheimer set a $50.00 price target on The Medicines and gave the company a “hold” rating in a research note on Wednesday, October 4th. Zacks Investment Research cut The Medicines from a “hold” rating to a “strong sell” rating in a research note on Tuesday, October 10th. Finally, Guggenheim initiated coverage on The Medicines in a report on Monday, October 23rd. They issued a “buy” rating and a $45.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $53.67.

Shares of The Medicines Company (NASDAQ:MDCO) opened at $26.94 on Friday. The Medicines Company has a 1-year low of $25.40 and a 1-year high of $55.95. The company has a quick ratio of 1.79, a current ratio of 2.31 and a debt-to-equity ratio of 3.42. The firm has a market capitalization of $1,910.64, a P/E ratio of -2.95 and a beta of 0.70.

The Medicines (NASDAQ:MDCO) last posted its earnings results on Wednesday, October 25th. The company reported ($0.42) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.37) by $0.95. The Medicines had a negative return on equity of 174.68% and a negative net margin of 767.94%. The firm had revenue of $16.87 million during the quarter, compared to analyst estimates of $26.06 million. During the same period in the previous year, the company earned ($0.64) EPS. The company’s revenue for the quarter was down 55.1% on a year-over-year basis. analysts predict that The Medicines Company will post -8.86 earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “SG Americas Securities LLC Purchases Shares of 5,340 The Medicines Company (MDCO)” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece of content on another website, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The original version of this piece of content can be read at https://www.com-unik.info/2017/12/23/sg-americas-securities-llc-purchases-shares-of-5340-the-medicines-company-mdco.html.

About The Medicines

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Institutional Ownership by Quarter for The Medicines (NASDAQ:MDCO)

What are top analysts saying about The Medicines? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for The Medicines and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit